Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials
Saad Z. Usmani, Hareth Nahi, Torben Plesner, Brendan M. Weiss, Nizar J. Bahlis, Andrew Belch, Peter M. Voorhees, Jacob P. Laubach, Niels W.C.J. van de Donk, Tahamtan Ahmadi, Clarissa Uhlar, Jianping Wang, Huaibao Feng, Ming Qi, Paul G. Richardson, Sagar Lonial
Topics & Concepts
DaratumumabMedicineMultiple myelomaSiriusRefractory (planetary science)Internal medicineOncologyPhases of clinical researchClinical trialLenalidomidePhysicsAstronomyAstrobiologyStarsMultiple Myeloma Research and TreatmentsUbiquitin and proteasome pathwaysProtein Degradation and Inhibitors